D. C. Palmer and N. P. Restifo, Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function, Trends Immunol, vol.30, issue.09, pp.197-202, 2009.

D. C. Palmer, Cish actively silences TCR signaling in CD8 + T cells to maintain tumor tolerance, J Exp Med, vol.212, pp.2095-2113, 2015.

R. B. Delconte, CIS is a potent checkpoint in NK cell-mediated tumor immunity, Nat Immunol, vol.17, pp.816-824, 2016.

E. M. Putz, Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology 6, e1267892, 2017.

, SCIeNtIfIC RepoRts |, vol.8, p.5336, 2018.

T. Landsman and D. J. Waxman, Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization, J Biol Chem, vol.280, pp.37471-37480, 2005.

A. Matsumoto, CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation, Blood, vol.89, pp.3148-3154, 1997.

A. Yoshimura, A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors, EMBO J, vol.14, pp.2816-2826, 1995.

S. Okabe, Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway, Exp Hematol, vol.27, issue.99, pp.94-100, 1999.

F. Verdier, Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein, J Biol Chem, vol.273, pp.28185-28190, 1998.

A. Matsumoto, Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice, Mol Cell Biol, vol.19, pp.6396-6407, 1999.

J. Piessevaux, L. De-ceuninck, D. Catteeuw, F. Peelman, and J. Tavernier, Elongin B/C recruitment regulates substrate binding by CIS, J Biol Chem, vol.283, pp.21334-21346, 2008.

J. Goedhart, Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93%, Nat Commun, vol.3, 2012.

S. C. Bunnell, V. A. Barr, C. L. Fuller, and L. E. Samelson, High-resolution multicolor imaging of dynamic signaling complexes in T cells stimulated by planar substrates, Sci STKE, vol.8, 2003.

V. A. Barr, Development of nanoscale structure in LAT-based signaling complexes, J Cell Sci, vol.129, p.194886, 2016.

G. Guittard, Absence of both Sos-1 and Sos-2 in peripheral CD4(+) T cells leads to PI3K pathway activation and defects in migration, Eur J Immunol, vol.45, pp.2389-2395, 2015.

S. A. Rosenberg and N. P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, vol.348, pp.62-68, 2015.

J. Couzin-frankel, Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, pp.1432-1433, 2013.

A. D. Fesnak, C. H. June, and B. L. Levine, Engineered T cells: the promise and challenges of cancer immunotherapy, Nat Rev Cancer, vol.16, pp.566-581, 2016.

S. J. Patel, Identification of essential genes for cancer immunotherapy, 2017.